Phaseline

Targets › NMNAT1

NMNAT1 (Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Ophthalmology; next expected readout Apr 2027.

Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can use triazofurin monophosphate (TrMP) as substrate. (UniProt, Q9HAN9)

Open in Phaseline: the race on NMNAT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University College, LondonNicotinamide
NAD+ precursor; supports mitochondrial function and neuroprotection
NMNAT1Phase 3Glaucoma, Open-AngleApr 2027

Conditions

Glaucoma, Open-Angle (1)

Modalities

small molecule (1)

Companies

University College, London (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.